2006
Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger
Wild P, Giedl J, Stoehr R, Junker K, Boehm S, van Oers J, Zwarthoff E, Blaszyk H, Fine S, Humphrey P, Dehner L, Amin M, Epstein J, Hartmann A. Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger. The Journal Of Pathology 2006, 211: 18-25. PMID: 17072825, DOI: 10.1002/path.2075.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlphapapillomavirusChildChild, PreschoolChromosome AberrationsChromosomes, Human, Pair 9DNA Mismatch RepairDNA Mutational AnalysisDNA, ViralFemaleGene Expression ProfilingGenes, p53HumansImmunohistochemistryIn Situ Hybridization, FluorescenceLoss of HeterozygosityMaleMicrosatellite InstabilityOligonucleotide Array Sequence AnalysisPapillomaPolymerase Chain ReactionReceptor, Fibroblast Growth Factor, Type 3Urologic NeoplasmsUrotheliumConceptsPatients 19 yearsUrothelial neoplasmsUrothelial papillomaMicrosatellite instabilityClinical outcomesHuman papillomavirusTP53 mutationsHigh-grade papillary urothelial carcinomaNIH consensus panelEvidence of diseaseFavorable clinical outcomeLow malignant potentialChromosome arm 9pPapillary urothelial carcinomaComparative genomic hybridizationPapillary urothelial neoplasmHPV positivityYounger patientsMultifocal tumorsUrothelial carcinomaUrothelial tumorsMalignant potentialPolymerase chain reactionConsensus panelKi-67
1994
Overexpression of p53 and HER-2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer
Marks J, Humphrey P, Wu K, Berry D, Bandarenko N, Kerns B, Iglehart J. Overexpression of p53 and HER-2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer. Annals Of Surgery 1994, 219: 332-341. PMID: 7909221, PMCID: PMC1243148, DOI: 10.1097/00000658-199404000-00002.Peer-Reviewed Original ResearchConceptsHER-2/neuEarly-stage breast cancerStage breast cancerHER-2/neu oncogeneBreast cancerPrognostic valueHER-2/neu proteinNeu oncogeneGenetic abnormalitiesDuke University Medical CenterFailure-free survivalProgesterone receptor contentCohort of patientsLimited prognostic valueIndependent prognostic valueShorter survival timeParaffin-embedded specimensUniversity Medical CenterHER-2/neu geneOverexpression of p53Common genetic abnormalityNodal statusRetrospective cohortLow estrogenTumor size
1993
Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias
Kohler M, Nishii H, Humphrey P, Saski H, Marks J, Bast R, Clarke-Pearson D, Boyd J, Berchuck A. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. American Journal Of Obstetrics And Gynecology 1993, 169: 690-694. PMID: 8372881, DOI: 10.1016/0002-9378(93)90644-x.Peer-Reviewed Original Research
1992
Clonal Origin of Epithelial Ovarian Carcinoma: Analysis by Loss of Heterozygosity, p53 Mutation, and X-Chromosome Inactivation
Jacobs I, Kohler M, Wiseman R, Marks J, Whitaker R, Kerns B, Humphrey P, Berchuck A, Ponder B, Bast R. Clonal Origin of Epithelial Ovarian Carcinoma: Analysis by Loss of Heterozygosity, p53 Mutation, and X-Chromosome Inactivation. Journal Of The National Cancer Institute 1992, 84: 1793-1798. PMID: 1433368, DOI: 10.1093/jnci/84.23.1793.Peer-Reviewed Original ResearchConceptsEpithelial ovarian carcinomaOvarian cancerOvarian carcinomaTumor depositsPrimary tumorPolyclonal diseaseLoss of heterozygosityClonal originSporadic epithelial ovarian carcinomaMultiple tumour depositsMonoclonal originMultiple primary tumorsPrimary ovarian tumorsPrimary ovarian cancerHereditary ovarian cancerPeripheral blood lymphocytesP53 gene mutationsX-chromosome inactivation analysisMetastatic depositsOvarian tumorsBlood lymphocytesPeritoneal surfacePeritoneal mesotheliumClinical strategiesP53 mutations